Literature DB >> 15971647

Prognostic implications of site of recurrence in patients with recurrent well-differentiated thyroid cancer.

Zeeshan Waseem1, Carsten E Palme, Paul Walfish, Jeremy L Freeman.   

Abstract

OBJECTIVE: The site of treatment failure in patients with recurrent well-differentiated thyroid carcinoma (WDTC) has implications for both the mode of salvage therapy and disease-specific prognosis. The objective of this study was to evaluate the prognostic significance of the site of failure in patients with recurrent WDTC.
DESIGN: Patients with recurrent thyroid cancer were identified retrospectively from 1963 to 2000.
SETTING: Data were retrieved from the thyroid cancer database at the Department of Otolaryngology-Head and Neck Surgery, Mount Sinai Hospital, Toronto (1963-2000).
METHODS: Patients were placed into four different groups according to their site of recurrence: group 1, local recurrence; group 2, regional recurrence; group 3, distant recurrence; and group 4, unspecified recurrence. Patient, tumour, and treatment data were collected and compared. The Kaplan-Meier method was used to calculate survival data, and curves were compared using the log rank test. MAIN OUTCOME MEASURES: Outcome included alive, no disease; alive with disease; dead, no disease; and dead of disease.
RESULTS: Seventy-three patients (21 male, 52 female; median age 44 years, range 18-84 years) were eligible for inclusion in this study. Relevant data were divided according to group 1, 22 patients; group 2, 24 patients; group 3, 13 patients; and group 4, 14 patients. The groups were comparable in terms of primary tumour and treatment factors. The actuarial disease-specific survival rate after salvage therapy was less significant in patients who developed a distant recurrence versus a local recurrence, a regional recurrence, or an unspecified recurrence (ie, 66% vs 95%, 88%, and 92%, respectively; p = .06).
CONCLUSIONS: Patients with distant recurrences have a poor prognosis, with a significant reduction in the actuarial disease-specific survival rate.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15971647     DOI: 10.2310/7070.2004.04013

Source DB:  PubMed          Journal:  J Otolaryngol        ISSN: 0381-6605


  5 in total

1.  Recurrent differentiated thyroid cancer: to cut or burn.

Authors:  Roberto Cirocchi; Stefano Trastulli; Alessandro Sanguinetti; Lorenzo Cattorini; Piero Covarelli; Domenico Giannotti; Giorgio Di Rocco; Fabio Rondelli; Francesco Barberini; Carlo Boselli; Alberto Santoro; Nino Gullà; Adriano Redler; Nicola Avenia
Journal:  World J Surg Oncol       Date:  2011-08-12       Impact factor: 2.754

2.  Long-term results of surgery for papillary thyroid carcinoma with local recurrence.

Authors:  Hiroki Uchida; Tsuneo Imai; Toyone Kikumori; Hironori Hayashi; Shigenori Sato; Sumiyo Noda; Ai Idota; Tetsuya Kiuchi
Journal:  Surg Today       Date:  2012-10-10       Impact factor: 2.549

3.  Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma.

Authors:  Gary L Clayman; Garima Agarwal; Beth S Edeiken; Steven G Waguespack; Dianna B Roberts; Steven I Sherman
Journal:  Thyroid       Date:  2011-12       Impact factor: 6.568

4.  Risk Factors for Recurrence in Filipinos with Well-Differentiated Thyroid Cancer.

Authors:  Tom Edward Ngo Lo; Abigail Uy Canto; Patricia Deanna D Maningat
Journal:  Endocrinol Metab (Seoul)       Date:  2015-10-20

5.  Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer.

Authors:  L Giovanella; M Imperiali; P Trimboli
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.